Should You Buy X4 Pharmaceuticals Inc (XFOR) Stock After it Is Lower By 33.71% in a Week?

X4 Pharmaceuticals Inc (XFOR) stock is down 33.71% over the past week and gets a Bearish rating from InvestorsObserver Sentiment Indicator.

X4 Pharmaceuticals Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on XFOR!

See Full XFOR Report

What is Stock Sentiment?

When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment. Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor. InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon. The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

What's Happening With XFOR Stock Today?

X4 Pharmaceuticals Inc (XFOR) stock is lower by -2.44% while the S&P 500 has gained 0.02% as of 10:17 AM on Tuesday, Dec 12. XFOR is down -$0.01 from the previous closing price of $0.61 on volume of 1,545,506 shares. Over the past year the S&P 500 is higher by 15.86% while XFOR is down -34.44%. XFOR lost -$0.79 per share in the over the last 12 months. To screen for more stocks like X4 Pharmaceuticals Inc click here.

More About X4 Pharmaceuticals Inc

X4 Pharmaceuticals Inc is clinical-stage biopharmaceutical company. It is focused on restoring the immune system function by developing therapeutics for the treatment of rare diseases. Its molecule therapeutics are antagonists of chemokine receptor CXCR4, which have the potential to treat a broad range of rare diseases, including primary immunodeficiencies (PIs) and cancer. Its product candidate, X4P-001, has completed a Phase 2 trial in patients with a rare genetic PI called Warts. The company is also developing X4P-002, a CXCR4 antagonist that has properties that could enable penetration of the blood-brain barrier and provide appropriate therapeutic exposures to treat brain cancers, including glioblastoma multiforme. Click Here to get the full Stock Report for X4 Pharmaceuticals Inc stock.